{
  "schema_version": "3.1.1-production",
  "doc_id": "CT-19862",
  "evaluation_id": "CT-19862",
  "extraction_date": "2022-06-29",
  "extraction_metadata": {
    "processing_version": "auto",
    "extraction_date": "2022-06-29",
    "parser": "auto",
    "annotateur_default": "auto",
    "niveau_confiance_default": 4,
    "source_files": {
      "F1": {
        "file_name": "ct_CT-19862_BUPENSAN_PIS_INS_HYBR_AvisDef_CT19862.pdf",
        "type": "CT",
        "page_count": 4
      }
    }
  },
  "template_detecte": "CT_modern",
  "section_taxonomy_version": "1.0",
  "SegmentIndex": [
    {
      "segment_id": "CT-19862_S1",
      "section_label_normalise": "SYNTHESE_DE_L_AVIS",
      "section_label_brut": "L’essentiel",
      "template_detecte": "CT_modern",
      "page_start": 1,
      "page_end": 1,
      "char_start": 0,
      "char_end": 0,
      "heading_text": "L’essentiel",
      "expected_fields": [],
      "routing_hint": "",
      "label_confidence": 0.95
    },
    {
      "segment_id": "CT-19862_S2",
      "section_label_normalise": "CONTEXTE",
      "section_label_brut": "Contexte",
      "template_detecte": "CT_modern",
      "page_start": 2,
      "page_end": 2,
      "char_start": 0,
      "char_end": 0,
      "heading_text": "Contexte",
      "expected_fields": [],
      "routing_hint": "",
      "label_confidence": 0.95
    },
    {
      "segment_id": "CT-19862_S3",
      "section_label_normalise": "INDICATIONS_THERAPEUTIQUES",
      "section_label_brut": "Indication",
      "template_detecte": "CT_modern",
      "page_start": 2,
      "page_end": 2,
      "char_start": 0,
      "char_end": 0,
      "heading_text": "Indication",
      "expected_fields": [],
      "routing_hint": "",
      "label_confidence": 0.95
    },
    {
      "segment_id": "CT-19862_S4",
      "section_label_normalise": "COMPARATEURS_PERTINENTS",
      "section_label_brut": "Comparateurs cliniquement pertinents",
      "template_detecte": "CT_modern",
      "page_start": 2,
      "page_end": 2,
      "char_start": 0,
      "char_end": 0,
      "heading_text": "Comparateurs cliniquement pertinents",
      "expected_fields": [],
      "routing_hint": "",
      "label_confidence": 0.95
    },
    {
      "segment_id": "CT-19862_S5",
      "section_label_normalise": "SERVICE_MEDICAL_RENDU",
      "section_label_brut": "Conclusions de la Commission - Service Médical Rendu",
      "template_detecte": "CT_modern",
      "page_start": 2,
      "page_end": 2,
      "char_start": 0,
      "char_end": 0,
      "heading_text": "Conclusions de la Commission",
      "expected_fields": [],
      "routing_hint": "",
      "label_confidence": 0.9
    },
    {
      "segment_id": "CT-19862_S6",
      "section_label_normalise": "INTERET_SANTE_PUBLIQUE",
      "section_label_brut": "Conclusions de la Commission - Intérêt de santé publique",
      "template_detecte": "CT_modern",
      "page_start": 3,
      "page_end": 3,
      "char_start": 0,
      "char_end": 0,
      "heading_text": "Conclusions de la Commission",
      "expected_fields": [],
      "routing_hint": "",
      "label_confidence": 0.9
    },
    {
      "segment_id": "CT-19862_S7",
      "section_label_normalise": "SERVICE_MEDICAL_RENDU",
      "section_label_brut": "Conclusions de la Commission - Service Médical Rendu (suite)",
      "template_detecte": "CT_modern",
      "page_start": 3,
      "page_end": 3,
      "char_start": 0,
      "char_end": 0,
      "heading_text": "Conclusions de la Commission",
      "expected_fields": [],
      "routing_hint": "",
      "label_confidence": 0.9
    },
    {
      "segment_id": "CT-19862_S8",
      "section_label_normalise": "AMELIORATION_SMR",
      "section_label_brut": "Amélioration du Service Médical Rendu",
      "template_detecte": "CT_modern",
      "page_start": 3,
      "page_end": 3,
      "char_start": 0,
      "char_end": 0,
      "heading_text": "Amélioration du Service Médical Rendu",
      "expected_fields": [],
      "routing_hint": "",
      "label_confidence": 0.95
    },
    {
      "segment_id": "CT-19862_S9",
      "section_label_normalise": "POPULATION_CIBLE",
      "section_label_brut": "Population cible",
      "template_detecte": "CT_modern",
      "page_start": 3,
      "page_end": 3,
      "char_start": 0,
      "char_end": 0,
      "heading_text": "Population cible",
      "expected_fields": [],
      "routing_hint": "",
      "label_confidence": 0.95
    },
    {
      "segment_id": "CT-19862_S10",
      "section_label_normalise": "RECOMMANDATIONS",
      "section_label_brut": "Recommandations de la Commission",
      "template_detecte": "CT_modern",
      "page_start": 3,
      "page_end": 3,
      "char_start": 0,
      "char_end": 0,
      "heading_text": "Recommandations de la Commission",
      "expected_fields": [],
      "routing_hint": "",
      "label_confidence": 0.95
    },
    {
      "segment_id": "CT-19862_S11",
      "section_label_normalise": "INFORMATIONS_ADMINISTRATIVES",
      "section_label_brut": "Informations administratives et réglementaires",
      "template_detecte": "CT_modern",
      "page_start": 4,
      "page_end": 4,
      "char_start": 0,
      "char_end": 0,
      "heading_text": "Informations administratives et réglementaires",
      "expected_fields": [],
      "routing_hint": "",
      "label_confidence": 0.95
    }
  ],
  "Identifiants_Produits_Liaison": [
    {
      "produit_id": "CT-19862_produit_1",
      "evaluation_id": "CT-19862",
      "produit_nom_commercial": "BUPENSAN",
      "dci": "buprénorphine",
      "code_cis": "Non renseigné",
      "code_cip13": "34009 302 489 8 0",
      "presentations": [
        {
          "presentation_id": "CT-19862_produit_1_pres_1",
          "produit_id": "CT-19862_produit_1",
          "forme_pharmaceutique": "comprimé sublingual",
          "forme_pharma_enum": "Oral_sublingual",
          "dosage_concentration": "4 mg",
          "voie_administration": "Sublinguale",
          "conditionnement": "Boite de 7 comprimés sous plaquette",
          "code_cip13": "34009 302 489 8 0",
          "evidence": []
        }
      ],
      "titulaire_amm": "G. L. Pharma France",
      "statut_reglementaire": "AMM standard",
      "statut_amm_enum": "AMM_standard",
      "evidence": [
        {
          "field": "produit_nom_commercial",
          "f": "F1",
          "p": 1,
          "s": "HAS • BU",
          "t": "HAS • BUPENSAN 4 mg, comprimé sublingual Comprimé sublingual",
          "m": "manual",
          "c": 0.95
        },
        {
          "field": "dci",
          "f": "F1",
          "p": 1,
          "s": "AVIS SUR",
          "t": "Buprénorphine",
          "m": "manual",
          "c": 0.95
        },
        {
          "field": "code_cip13",
          "f": "F1",
          "p": 4,
          "s": "BUPENSAN",
          "t": "CIP : 34009 302 489 8 0",
          "m": "manual",
          "c": 0.95
        },
        {
          "field": "titulaire_amm",
          "f": "F1",
          "p": 4,
          "s": "Demandeur",
          "t": "G. L. Pharma France",
          "m": "manual",
          "c": 0.95
        }
      ]
    },
    {
      "produit_id": "CT-19862_produit_2",
      "evaluation_id": "CT-19862",
      "produit_nom_commercial": "SUBUTEX",
      "dci": "buprénorphine",
      "code_cis": "Non renseigné",
      "code_cip13": "Non renseigné",
      "presentations": [
        {
          "presentation_id": "CT-19862_produit_2_pres_1",
          "produit_id": "CT-19862_produit_2",
          "forme_pharmaceutique": "comprimé sublingual",
          "forme_pharma_enum": "Oral_sublingual",
          "dosage_concentration": "8 mg",
          "voie_administration": "Sublinguale",
          "conditionnement": "Non renseigné",
          "code_cip13": "Non renseigné",
          "evidence": []
        }
      ],
      "titulaire_amm": "Non renseigné",
      "statut_reglementaire": "Non renseigné",
      "statut_amm_enum": "Non renseigné",
      "evidence": [
        {
          "field": "produit_nom_commercial",
          "f": "F1",
          "p": 2,
          "s": "Cette spéci",
          "t": "Cette spécialité est un hybride de la spécialité de référence SUBUTEX 8 mg, comprimé sublingual.",
          "m": "manual",
          "c": 0.95
        }
      ]
    }
  ],
  "Evaluations_HAS": [
    {
      "evaluation_id": "CT-19862",
      "Num_avis": "CT-19862",
      "produit_nom": "BUPENSAN 4 mg, comprimé sublingual",
      "dci": "buprénorphine",
      "type_avis": "Inscription d'un hybride",
      "type_avis_enum": "Inscription",
      "forme": "comprimé sublingual",
      "dosage": "4 mg",
      "indication": "Traitement substitutif par voie sublinguale de la pharmacodépendance aux opioïdes chez l'adulte et l'adolescent de plus de 15 ans, dans le cadre d'une thérapeutique globale de prise en charge médicale, sociale et psychologique.",
      "classe_ATC": "N07BC01",
      "pathologie": "Dépendance aux opioïdes",
      "maladie_rare": false,
      "ligne_traitement": "Traitement substitutif",
      "ligne_traitement_enum": "Autre_Substitution",
      "sous_groupe_population": "Adultes et adolescents de plus de 15 ans",
      "cim10_principal": "Non renseigné",
      "cim10_secondaires": [],
      "libelle_cim10": "Non renseigné",
      "source_cim10": "Non renseigné",
      "aire_therapeutique_niveau_1": "Système nerveux",
      "aire_therapeutique_niveau_2": "Produits utilisés en addictologie",
      "aire_therapeutique_niveau_3": "Traitement de substitution aux opioïdes",
      "source_aire_therapeutique": "Déduit ATC N07BC01",
      "design_etude": "Non renseigné",
      "niveau_preuve_brut": "Non renseigné",
      "niveau_preuve_interprete": "Non renseigné",
      "besoin_medical_brut": "Non renseigné",
      "besoin_medical_interprete": "Non renseigné",
      "pathologie_categorie_enum": "Autre",
      "age_restriction_flag": true,
      "age_restriction_detail": "Adulte et adolescent > 15 ans",
      "biomarqueur_requis": "Aucun",
      "design_enum": "Non renseigné",
      "gravite_patho": "La dépendance aux opiacés expose à des symptômes de tolérance pharmacologique, des manifestations de sevrage et à toutes les conséquences psycho-comportementales et sociales de la perte de contrôle de la consommation. Du fait de leur puissance addictive, ces substances exposent à des risques de surdose mortelle. La pratique d'injections expose à des risques de contaminations infectieuses (infection VIH et hépatite C). La prévalence de troubles psychiques concomitants est très élevée.",
      "gravite_patho_enum": [
        "Grave"
      ],
      "type_population_cible": "Adultes et adolescents de plus de 15 ans",
      "pertinence_concurrence_therapeutique": "Les comparateurs cliniquement pertinents sont les spécialités à base de buprénorphine actuellement remboursables dans l'indication de l'AMM.",
      "caractere_innovant_reconnu": false,
      "perte_de_chance_citee": false,
      "historique_Has_produit": "Non renseigné",
      "historique_ASMR_comparateurs": "Non renseigné",
      "concurrence_therapeutique_recente": "De nombreuses spécialités à base de buprénorphine 4 mg sont déjà inscrites sur les listes de remboursement dans cette indication.",
      "vote_unanimite": null,
      "nb_votants": null,
      "nb_voix_pour": null,
      "nb_voix_contre": null,
      "nb_abstentions": null,
      "date_evaluation": "2022-06-29",
      "transcription_textuelle": "Non renseigné",
      "extraits_arguments": [],
      "evidence": [
        {
          "field": "produit_nom",
          "f": "F1",
          "p": 1,
          "s": "HAS • BU",
          "t": "HAS • BUPENSAN 4 mg, comprimé sublingual Comprimé sublingual",
          "m": "manual",
          "c": 0.95
        },
        {
          "field": "dci",
          "f": "F1",
          "p": 1,
          "s": "AVIS SUR",
          "t": "Buprénorphine",
          "m": "manual",
          "c": 0.95
        },
        {
          "field": "type_avis",
          "f": "F1",
          "p": 1,
          "s": "Mise à dis",
          "t": "Mise à disposition d'un hybride",
          "m": "manual",
          "c": 0.95
        },
        {
          "field": "indication",
          "f": "F1",
          "p": 2,
          "s": "Indication",
          "t": "Traitement substitutif par voie sublinguale de la pharmacodépendance aux opioïdes chez l’adulte et l’adolescent de plus de 15 ans, dans le cadre d'une thérapeutique globale de prise en charge médicale, sociale et psychologique.",
          "m": "manual",
          "c": 0.95
        },
        {
          "field": "classe_ATC",
          "f": "F1",
          "p": 4,
          "s": "Code ATC",
          "t": "N07BC01",
          "m": "manual",
          "c": 0.95
        },
        {
          "field": "pathologie",
          "f": "F1",
          "p": 1,
          "s": "➔ Dépendan",
          "t": "➔ Dépendance aux opioïdes",
          "m": "manual",
          "c": 0.95
        },
        {
          "field": "maladie_rare",
          "f": "F1",
          "p": 1,
          "s": "Non renseigné",
          "t": "Non renseigné",
          "m": "manual",
          "c": 1.0
        },
        {
          "field": "ligne_traitement",
          "f": "F1",
          "p": 1,
          "s": "Avis favor",
          "t": "Avis favorable au remboursement dans le traitement substitutif de la pharmacodépendance aux opioïdes",
          "m": "manual",
          "c": 0.95
        },
        {
          "field": "sous_groupe_population",
          "f": "F1",
          "p": 1,
          "s": "Le traiteme",
          "t": "Le traitement est réservé aux adultes et adolescents de plus de 15 ans",
          "m": "manual",
          "c": 0.95
        },
        {
          "field": "gravite_patho",
          "f": "F1",
          "p": 2,
          "s": "Service Méd",
          "t": "La dépendance aux opiacés expose à des symptômes de tolérance pharmacologique, des manifestations de sevrage et à toutes les conséquences psycho-comportementales et sociales de la perte de contrôle de la consommation. Du fait de leur puissance addictive, ces substances exposent à des risques de surdose mortelle. La pratique d'injections expose à des risques de contaminations infectieuses (infection VIH et hépatite C). La prévalence de troubles psychiques concomitants est très élevée.",
          "m": "manual",
          "c": 0.95
        },
        {
          "field": "type_population_cible",
          "f": "F1",
          "p": 1,
          "s": "Le traiteme",
          "t": "Le traitement est réservé aux adultes et adolescents de plus de 15 ans",
          "m": "manual",
          "c": 0.95
        },
        {
          "field": "pertinence_concurrence_therapeutique",
          "f": "F1",
          "p": 2,
          "s": "Comparateur",
          "t": "Les comparateurs cliniquement pertinents sont les spécialités à base de buprénorphine actuellement remboursables dans l’indication de l’AMM.",
          "m": "manual",
          "c": 0.95
        },
        {
          "field": "caractere_innovant_reconnu",
          "f": "F1",
          "p": 1,
          "s": "Quel progrè",
          "t": "Pas de progrès par rapport aux spécialités à base de buprénorphine déjà inscrites.",
          "m": "manual",
          "c": 0.95
        },
        {
          "field": "concurrence_therapeutique_recente",
          "f": "F1",
          "p": 2,
          "s": "De nombreus",
          "t": "De nombreuses spécialités à base de buprénorphine 4 mg sont déjà inscrites sur les listes de remboursement dans cette indication.",
          "m": "manual",
          "c": 0.95
        },
        {
          "field": "date_evaluation",
          "f": "F1",
          "p": 1,
          "s": "Adopté par",
          "t": "Adopté par la Commission de la transparence le 29 juin 2022",
          "m": "manual",
          "c": 0.95
        }
      ],
      "_meta": {}
    }
  ],
  "Essais_Cliniques": [
    {
      "essai_id": "CT-19862_essai_principal",
      "evaluation_id": "CT-19862",
      "nom_essai": "Étude principale (nom non spécifié)",
      "nct_number": "Non renseigné",
      "design": "Non renseigné",
      "population_cible": "Adultes et adolescents de plus de 15 ans avec pharmacodépendance aux opioïdes",
      "comparateur_utilise": "Non renseigné",
      "nb_patient_traitement": null,
      "nb_patient_comparateur": null,
      "resultat_global": "Non renseigné",
      "QoL_flag": null,
      "niveau_preuve": "Non renseigné",
      "pooling_flag": null,
      "population_dedoublée": null,
      "suivi_median_mois": null,
      "arret_premature_flag": false,
      "duree_traitement_moyenne_mois": null,
      "phase": "Non renseigné",
      "aveugle": "Non renseigné",
      "randomisation_flag": null,
      "randomisation_ratio": "Non renseigné",
      "stratification_flag": null,
      "stratification_facteurs": [],
      "population_analyse_principale": "Non renseigné",
      "date_cutoff_donnees": "Non renseigné",
      "duree_suivi_prevu_mois": null,
      "maturite_donnees": "Non renseigné",
      "age_min_num": 15,
      "age_max_num": null,
      "ligne_traitement_essai_enum": "Autre_Substitution",
      "comparateur_type_enum": "Non renseigné",
      "efficacite_demontree": null,
      "magnitude_effet_categorie": "Non renseigné",
      "maturite_pct": null,
      "arret_premature_raison": "Non applicable",
      "arret_premature_date": "Non renseigné",
      "analyse_interimaire_plannifiee": null,
      "qol_instruments": [],
      "qol_resultats_brut": "Non renseigné",
      "qol_difference_cliniquement_pertinente": null,
      "qol_favorable": null,
      "nb_facteurs_stratification": null,
      "nb_patients_inclus": "Non renseigné",
      "nb_patients_inclus_par_pays": [],
      "date_fin_inclusion": "Non renseigné",
      "nb_analyses_intermediaire": null,
      "date_analyses_intermediares_mois": [],
      "evidence": [
        {
          "field": "population_cible",
          "f": "F1",
          "p": 2,
          "s": "Indication",
          "t": "Traitement substitutif par voie sublinguale de la pharmacodépendance aux opioïdes chez l’adulte et l’adolescent de plus de 15 ans",
          "m": "manual",
          "c": 0.9
        },
        {
          "field": "age_min_num",
          "f": "F1",
          "p": 2,
          "s": "Indication",
          "t": "adolescent de plus de 15 ans",
          "m": "manual",
          "c": 0.9
        }
      ],
      "_meta": {}
    }
  ],
  "Critères_Jugement": [
    {
      "critere_id": "CT-19862_essai_principal_crit_efficacite",
      "evaluation_id": "CT-19862",
      "essai_id": "CT-19862_essai_principal",
      "nom_critere": "Efficacité dans le traitement substitutif",
      "nature_critere": "Non renseigné",
      "unite_mesure": "Non renseigné",
      "hierarchie_critere": "Non renseigné",
      "ordre_hierarchie": null,
      "critere_co_primaire_groupe": null,
      "condition_test": null,
      "ajustement_alpha_realise": false,
      "methode_ajustement_alpha": "Non applicable",
      "alpha_ajuste": null,
      "alpha_global_famille": null,
      "nombre_tests_famille": null,
      "test_statistique_utilise": "Non renseigné",
      "modele_ajuste": null,
      "facteurs_ajustement": [],
      "analyse_stratifiee": null,
      "valeur_groupe_traitement": "Non renseigné",
      "valeur_groupe_comparateur": "Non renseigné",
      "gain_absolu": "Non renseigné",
      "gain_absolu_num": null,
      "gain_relatif": "Non renseigné",
      "gain_relatif_num": null,
      "HR_RR_OR": "Non renseigné",
      "HR_RR_OR_num": null,
      "IC95": "Non renseigné",
      "IC95_low_num": null,
      "IC95_high_num": null,
      "p_value": "Non renseigné",
      "p_value_num": null,
      "unite_normalisee": "Autre",
      "type_effet": "Autre",
      "significativite_statistique": false,
      "critere_atteint": false,
      "degre_signification": "Non_teste",
      "pertinence_clinique": "Non renseigné",
      "commentaire_has_resultat": "Non renseigné",
      "is_primary": false,
      "evidence": [],
      "_meta": {}
    },
    {
      "critere_id": "CT-19862_essai_principal_crit_tolerance",
      "evaluation_id": "CT-19862",
      "essai_id": "CT-19862_essai_principal",
      "nom_critere": "Rapport efficacité/effets indésirables",
      "nature_critere": "Non renseigné",
      "unite_mesure": "Non renseigné",
      "hierarchie_critere": "Non renseigné",
      "ordre_hierarchie": null,
      "critere_co_primaire_groupe": null,
      "condition_test": null,
      "ajustement_alpha_realise": false,
      "methode_ajustement_alpha": "Non applicable",
      "alpha_ajuste": null,
      "alpha_global_famille": null,
      "nombre_tests_famille": null,
      "test_statistique_utilise": "Non renseigné",
      "modele_ajuste": null,
      "facteurs_ajustement": [],
      "analyse_stratifiee": null,
      "valeur_groupe_traitement": "Important",
      "valeur_groupe_comparateur": "Non renseigné",
      "gain_absolu": "Non renseigné",
      "gain_absolu_num": null,
      "gain_relatif": "Non renseigné",
      "gain_relatif_num": null,
      "HR_RR_OR": "Non renseigné",
      "HR_RR_OR_num": null,
      "IC95": "Non renseigné",
      "IC95_low_num": null,
      "IC95_high_num": null,
      "p_value": "Non renseigné",
      "p_value_num": null,
      "unite_normalisee": "Autre",
      "type_effet": "Autre",
      "significativite_statistique": false,
      "critere_atteint": false,
      "degre_signification": "Non_teste",
      "pertinence_clinique": "Non renseigné",
      "commentaire_has_resultat": "Le rapport efficacité/ effets indésirables de BUPENSAN est important.",
      "is_primary": false,
      "evidence": [
        {
          "field": "commentaire_has_resultat",
          "f": "F1",
          "p": 2,
          "s": "Service Méd",
          "t": "Le rapport efficacité/ effets indésirables de BUPENSAN est important.",
          "m": "manual",
          "c": 0.95
        }
      ],
      "_meta": {}
    }
  ],
  "Tolérance": [
    {
      "tolerance_id": "CT-19862_essai_principal_tol",
      "evaluation_id": "CT-19862",
      "essai_id": "CT-19862_essai_principal",
      "ae_total_pct": null,
      "ae_total_pct_comparateur": null,
      "sae_pct": null,
      "sae_pct_comparateur": null,
      "discontinuations_ae_pct": null,
      "discontinuations_ae_pct_comparateur": null,
      "deaths_ae_n": null,
      "deaths_ae_n_comparateur": null,
      "sae_data_available": false,
      "sae_superieur_comparateur": null,
      "deaths_reported": false,
      "EI_graves_detailles": [],
      "EI_frequents_detailles": [],
      "ei_grade_max": "Non renseigné",
      "deces_detailles": [],
      "signal_securite_flag": false,
      "signal_securite_detailles": [],
      "signal_ansm_flag": false,
      "EI_graves": "Non renseigné",
      "EI_frequents": "Non renseigné",
      "deces": "Non renseigné",
      "signal_securite": "Non renseigné",
      "evidence": [],
      "_meta": {}
    }
  ],
  "Comparateurs_Essai": [],
  "Comparateurs_HAS": [
    {
      "comparateur_id": "CT-19862_compHAS_1",
      "evaluation_id": "CT-19862",
      "nom_comparateur_HAS": "Spécialités à base de buprénorphine",
      "type_comparateur": "Traitement_actif",
      "comparateur_standard_soin": "Oui",
      "famille_comparateur": "Traitement_substitution_opioïdes",
      "evidence": [
        {
          "field": "nom_comparateur_HAS",
          "f": "F1",
          "p": 2,
          "s": "Comparateur",
          "t": "Les comparateurs cliniquement pertinents sont les spécialités à base de buprénorphine actuellement remboursables dans l’indication de l’AMM.",
          "m": "manual",
          "c": 0.95
        }
      ],
      "_meta": {}
    }
  ],
  "Arguments_Decisionnels": [],
  "Données_Contexte": {
    "contexte_id": "CT-19862_ctx",
    "evaluation_id": "CT-19862",
    "ISP": "Non renseigné",
    "acces_precoce": "Aucun",
    "date_debut_acces_precoce": "Non renseigné",
    "date_fin_acces_precoce": "Non renseigné",
    "duree_acces_precoce_mois": null,
    "nombre_patients_acces_precoce": null,
    "conditions_arret_acces_precoce": "Non renseigné",
    "ISP_flag": false,
    "ISP_categorie": "Pas_ISP",
    "type_acces_precoce_enum": "Aucun",
    "statut_reglementaire_ema": "AMM_standard",
    "date_AMM_ema": "2022-03-01",
    "date_avis_chmp": "Non renseigné",
    "innovation_therapeutique_ema": false,
    "designation_orpheline_ema": false,
    "prime_ema": false,
    "obligations_post_amm": [],
    "echeance_reexamen_amm": "Non renseigné",
    "nb_obligations_post_amm": 0,
    "evaluation_internationale": "Non renseigné",
    "pays_evaluations": [],
    "decisions_internationales": [],
    "nb_decisions_internationales": 0,
    "RDCR": "Non renseigné",
    "RDCR_num": null,
    "RDCR_intervalle": null,
    "RDCR_vs_seuil": "Non renseigné",
    "model_type": "Non renseigné",
    "perspective": "Non renseigné",
    "horizon_annees": null,
    "horizon_justification": "Non renseigné",
    "discount_rate_costs": null,
    "discount_rate_qalys": null,
    "DSA_flag": null,
    "PSA_flag": null,
    "scenario_analyses": [],
    "major_reserves": [],
    "nb_reserves_majeures": 0,
    "impact_budgetaire_prevu": "Non renseigné",
    "impact_budgetaire_annee_1": null,
    "impact_budgetaire_annee_5": null,
    "impact_budgetaire_horizon": null,
    "hypothese_population_cible": null,
    "hypothese_penetration_marche_pct": null,
    "reserves_impact_budgetaire": [],
    "reserves_majeures": false,
    "population_cible_france": "Non renseigné",
    "population_cible_nombre": null,
    "population_cible_intervalle": null,
    "source_estimation_population": "Non renseigné",
    "incertitude_population": "Non renseigné",
    "population_cible_mediane": null,
    "suivi_post_inscription": false,
    "nature_suivi_post_inscription": "Non renseigné",
    "delai_suivi_mois": null,
    "delai_suivi_justification": "Non renseigné",
    "conditions_suivi": "Non renseigné",
    "echeance_suivi": "Non renseigné",
    "impact_si_non_realise": "Non précisé",
    "delai_soumission_dossier": "Non renseigné",
    "delai_complement_demande": false,
    "dates_complement_demande": [],
    "delai_audition": false,
    "date_audition": "Non renseigné",
    "nb_total_reserves": null,
    "nb_total_reserves_mineures": null,
    "nb_totales_reserves_importantes": null,
    "nb_totales_reserves_majeures": null,
    "SMR_avant_audition_enum": "Non_renseigné",
    "SMR_apres_audition_enum": "Non_renseigné",
    "ASMR_avant_audition_enum": "Non_renseigné",
    "ASMR_après_audition_enum": "Non_renseigné",
    "type_critère_justification": "Non renseigné",
    "valeur_critère": "Non renseigné",
    "impact_décision": "Non renseigné",
    "estimation_mesure_impact": "Non renseigné",
    "evidence": [
      {
        "field": "date_AMM_ema",
        "f": "F1",
        "p": 4,
        "s": "AMM",
        "t": "Date initiale (procédure décentralisée) : 01/03/2022",
        "m": "manual",
        "c": 0.95
      },
      {
        "field": "statut_reglementaire_ema",
        "f": "F1",
        "p": 4,
        "s": "Non renseigné",
        "t": "Non renseigné",
        "m": "manual",
        "c": 1.0
      }
    ],
    "_meta": {}
  },
  "Données_Textuelles": {
    "evaluation_id": "CT-19862",
    "texte_brut": "Non renseigné",
    "embedding": null,
    "evidence": [],
    "_meta": {}
  },
  "SMR_ASMR_Par_Indication": [],
  "Posologie_Par_Indication": [],
  "Timeline_Evenements": [
    {
      "event_id": "CT-19862_event_AMM_01",
      "evaluation_id": "CT-19862",
      "event_type": "AMM_EMA_DECISION",
      "event_date": "2022-03-01",
      "detail_brut": "Date initiale AMM (procédure décentralisée)",
      "source_doc": "F1 page 4",
      "detail_type_specifique": "Non renseigné",
      "acteurs_impliques": [],
      "duree_evenement_jours": null,
      "reference_externe": "Non renseigné",
      "delai_amm_ct_jours": null,
      "delai_ct_jo_jours": null,
      "evidence": [
        {
          "field": "event_date",
          "f": "F1",
          "p": 4,
          "s": "AMM",
          "t": "Date initiale (procédure décentralisée) : 01/03/2022",
          "m": "manual",
          "c": 0.95
        }
      ],
      "_meta": {}
    },
    {
      "event_id": "CT-19862_event_CT_01",
      "evaluation_id": "CT-19862",
      "event_type": "ADOPTION_CT",
      "event_date": "2022-06-29",
      "detail_brut": "Adopté par la Commission de la transparence",
      "source_doc": "F1 page 1",
      "detail_type_specifique": "Non renseigné",
      "acteurs_impliques": [],
      "duree_evenement_jours": null,
      "reference_externe": "Non renseigné",
      "delai_amm_ct_jours": null,
      "delai_ct_jo_jours": null,
      "evidence": [
        {
          "field": "event_date",
          "f": "F1",
          "p": 1,
          "s": "Adopté par",
          "t": "Adopté par la Commission de la transparence le 29 juin 2022",
          "m": "manual",
          "c": 0.95
        }
      ],
      "_meta": {}
    }
  ],
  "Timeline_Delais": {
    "evaluation_id": "CT-19862",
    "delai_amm_ct_jours": 120,
    "delai_transcription_ct_jours": null,
    "delai_audition_ct_jours": null,
    "complement_demande_mentionne": false,
    "audition_realisee": false,
    "evidence": [],
    "_meta": {}
  },
  "Features_Modele": {
    "evaluation_id": "CT-19862",
    "is_orphan": false,
    "classe_ATC_l2": "N07B",
    "aire_therapeutique": "Système nerveux",
    "type_avis_enum": "Inscription",
    "innovation_reconnue": false,
    "perte_de_chance_citee": false,
    "ligne_traitement_num": null,
    "is_rct": false,
    "n_essais": 1,
    "n_rct": 0,
    "presence_qol": false,
    "effet_principal_magnitude_num": null,
    "critere_principal_dur": false,
    "suivi_median_mois_max": null,
    "sae_pct_num": null,
    "discontinuations_pct_num": null,
    "critere_principal_description": "Efficacité dans le traitement substitutif",
    "p_value_log10": null,
    "ceesp_present": false,
    "rdcr_num": null,
    "rdcr_log": null,
    "impact_budget_cat": "Non renseigné",
    "reserves_majeures": false,
    "nb_reserves_majeures": 0,
    "vote_unanimite": null,
    "nb_votants": null,
    "voix_pour_pct": null,
    "association_patient_intervenue": false,
    "comparateur_placebo": false,
    "comparateur_soc": true,
    "nb_clockstops": 0,
    "annee_ct": 2022,
    "trimestre_ct": 2,
    "template_ere": "CT_modern",
    "missingness_indicators": "Non renseigné",
    "evidence": [],
    "_meta": {}
  },
  "Relations": [
    {
      "src_type": "EVALUATION",
      "src_id": "CT-19862",
      "tgt_type": "TRIAL",
      "tgt_id": "CT-19862_essai_principal",
      "label": "EVAL_HAS_TRIAL"
    },
    {
      "src_type": "TRIAL",
      "src_id": "CT-19862_essai_principal",
      "tgt_type": "CRITERE",
      "tgt_id": "CT-19862_essai_principal_crit_efficacite",
      "label": "TRIAL_HAS_CRIT"
    },
    {
      "src_type": "TRIAL",
      "src_id": "CT-19862_essai_principal",
      "tgt_type": "CRITERE",
      "tgt_id": "CT-19862_essai_principal_crit_tolerance",
      "label": "TRIAL_HAS_CRIT"
    },
    {
      "src_type": "TRIAL",
      "src_id": "CT-19862_essai_principal",
      "tgt_type": "TOLERANCE",
      "tgt_id": "CT-19862_essai_principal_tol",
      "label": "TRIAL_HAS_TOL"
    }
  ],
  "Annotation_View": []
}